PVR and neoplasm: Consistent with our human CAR-T data, mCD155 CAR-T cells exhibited robust and specific cytotoxicity against CD19–/low CD155+ tumor cells such as KPC and C1498, whereas mCD19 CAR-T cells showed minimal activity (Supplemental Figure 10, H and I), further confirming the antigen-specific activity of mCD155 CAR-T cells.